Warren RB, Weiss A, Felding J, Sommer MOA. Population pharmacokinetic–pharmacodynamic relationship of
orismilast, a potent and selective PDE4B/D inhibitor, in atopic dermatitis.
Dermatol Ther (Heidelb). 2025 Apr;15(4):831–839.
doi:10.1007/s13555-025-01371-9.
Silverberg JI, Eichenfield LF, Blauvelt A, et al. Orismilast, a PDE4B/D inhibitor, in moderate‑to‑severe atopic
dermatitis: Efficacy and safety from a multicenter, randomized, placebo‑controlled,
phase 2b dose‑ranging study
(ADESOS). Br J Dermatol. 2025 Jan 7. doi:10.1093/bjd/ljae507.
Frederiksen CG, Sedeh FB, Taudorf EH, Saunte DM, Jemec GBE. Orismilast for the treatment of mild to severe hidradenitis
suppurativa: Week 16 data
from OSIRIS, a Phase 2a,
open‑label, single‑centre, single‑arm, dose‑finding clinical trial. J
Eur Acad Dermatol Venereol. 2024 May;38(5):920–930.
doi:10.1111/jdv.19770.
Warren RB, French LE, Blauvelt A, et al. Orismilast in moderate‑to‑severe psoriasis: Efficacy and safety
from a 16‑week, randomized, double‑blinded, placebo‑controlled, dose‑finding,
phase 2b trial (IASOS).
J Am Acad Dermatol. 2024;90(3):494–503.
doi:10.1016/j.jaad.2023.11.005.
Blauvelt A, Langley RG, Gordon KB, et al. Next‑generation PDE4 inhibitors that selectively target PDE4B/D
subtypes: A narrative review. Dermatol Ther (Heidelb). 2023
Dec;13(12):3031–3042. doi:10.1007/s13555-023-01054-3.
Warren RB, Strober B, Silverberg JI, et al. Oral orismilast: Efficacy and safety in moderate‑to‑severe
psoriasis and development of modified release tablets. J Eur Acad
Dermatol Venereol. 2023 Apr;37(4):711–720. doi:10.1111/jdv.18812. Epub
2023 Jan 18.
Silverberg JI, French LE, Warren RB, et al. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. J Eur Acad Dermatol Venereol. 2023
Apr;37(4):721–729. doi:10.1111/jdv.18818. Epub 2023 Jan 18.
Mild-to-Moderate
13,4M suffers from Psoriasis in the US, EU5 and Japan
PDE4 inhibitor
Dermatology market and include
topical roflumilast cream
PDE4 Market and include
topical roflumilast cream
Moderate-to-servere
People in the US suffer from Psoriasis
TNF-Q + 11-17
Plaque psoriasis and atopic
dermatitis
Acim quam ratem eos dis ma
doluptatist
Checkpoint-for Psoriasis
People in EU5 suffer from Psoriasis
Keratinoc
Exerting anti-inflammatory effect
reducing psoriasis scale formation
PDE4 Market and include
topical roflumilast cream
Dr. Andrew Blauvelt, Dermatologist, investigator and president of the Oregon Medical Research, talks about the next-generation of PDE4 inhibitors.
Professor of Dermatology Jonathan Silverberg presented new data on orismilast at the 31st EADV Congress, 7-10 September 2022.
